3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People’s Republic of China.